Siteman | Strategic Alliance Partners

Latest from Siteman

Motixafortide/G-CSF Results in 4.9-Fold Increase in Achieving Target Stem-Cell Mobilization for Transplant in Myeloma

May 04, 2021

The addition of motixafortide to granulocyte colony stimulating factor resulted in a 4.9-fold increase in achieving target stem-cell mobilization for autologous bone marrow transplantation in up to 2 apheresis sessions vs G-CSF alone in patients with multiple myeloma, meeting the primary end point of the phase 3 GENESIS trial.

Breast Cancer: Chaired by Cynthia X. Ma, MD, PhD

October 20, 2020

Early detection, personalized treatment approaches, and increased situational awareness have improved cancer patient survival rates. Ongoing dialogue among leading experts can only improve patient outcomes and advance the field of oncology.

Siteman Cancer Center Awarded $7.8 Million to Expand Clinical Trials Access

August 02, 2019

Physicians at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis have been awarded a $7.8 million grant from the National Cancer Institute to play a leading role in designing, conducting and enrolling patients in clinical trials through the NCI